ABIONYX Pharma Logo

ABIONYX Pharma

ABNX | PA

Overview

Corporate Details

ISIN(s):
FR0012616852 (+1 more)
LEI:
969500785J7VIC5YPC96
Country:
France
Address:
33 AVENUE GEORGES POMPIDOU, 31130 BALMA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ABIONYX Pharma is a new-generation biotechnology company focused on discovering and developing innovative therapies for diseases with no existing or effective treatments, including rare conditions. The company specializes in creating drugs for renal and ophthalmological diseases. It leverages its expertise in lipid science to develop novel treatments, including new High-Density Lipoprotein (HDL) vectors for targeted drug delivery and apolipoprotein A-I (apoA-I)-based therapeutics.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for ABIONYX Pharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 217.2 KB
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.1 KB
2025-07-03 19:35
Transaction in Own Shares
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 532.3 KB
2025-07-03 19:35
Capital/Financing Update
Acquisition or disposal of the issuer's own shares / Information relating to th…
English 557.0 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Inside Information / Other news releases
English 206.8 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 221.2 KB
2025-06-06 18:15
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 273.9 KB
2025-06-03 18:00
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.3 KB
2025-06-03 18:00
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 218.9 KB
2025-05-28 18:00
Earnings Release
Quarterly financial reporting / First quarter financial report
English 315.4 KB
2025-05-28 18:00
Earnings Release
Information financière trimestrielle / Information financière du premier trimes…
French 282.2 KB
2025-05-06 21:33
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 220.6 KB
2025-05-06 21:33
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 201.5 KB
2025-04-03 20:16
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 220.6 KB
2025-04-03 20:16
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 201.4 KB

Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-28 N/A Other Buy 53,913 N/A

Peer Companies

Company Country Ticker View
H. Lundbeck A Logo
Global pharmaceutical company creating innovative treatments for brain diseases.
Denmark HLUN
Hong Kong N/A
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
Idorsia Ltd Logo
Develops novel medicines for CNS, cardiovascular, immunological, and orphan diseases.
Switzerland IDIA
Immuno-Biological Laboratories Co., Ltd. Logo Japan 4570
Indivior PLC Logo
A global pharmaceutical firm developing treatments for addiction and mental illness.
United Kingdom INDV
Infant Bacterial Therapeutics Logo
Developing microbiome therapies for premature infants to prevent life-threatening intestinal disease.
Sweden IBT
Intercure Ltd. Logo
Producer of pharma-grade, GMP-certified medical cannabis products for patients outside North America.
Israel INCR
Intervacc AB Logo
Develops recombinant protein vaccines for animal health, led by its vaccine for equine strangles.
Sweden IVACC
Ipsen Logo
Develops transformative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN